Who are AZA capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Merital, Isoniazid, Circadin, Sulide, Cadral, L-Tryptophan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aza-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AZA capsules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZA capsules (AZA capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 3 Immunosuppressant Myeloperoxidase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

AZA capsules (AZA capsules) — Centre Hospitalier Universitaire, Amiens. AZA capsules work by inhibiting the enzyme myeloperoxidase, which is involved in the production of reactive oxygen species.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZA capsules TARGET	AZA capsules	Centre Hospitalier Universitaire, Amiens	phase 3	Immunosuppressant	Myeloperoxidase
Merital	NOMIFENSINE		marketed	nomifensine	Hemoglobin HbA, Myeloperoxidase, 5-hydroxytryptamine receptor 1A	1984-01-01
Isoniazid	ISONIAZID	Epic Pharma Llc	marketed	Antimycobacterial [EPC]	Myeloperoxidase	1952-01-01
Circadin	Circadin	Neurim Pharmaceuticals Ltd.	marketed		Cytochrome P450 1B1, Myeloperoxidase, Nuclear receptor ROR-alpha
Sulide	NIMESULIDE		marketed	nimesulide	Myeloperoxidase, Aromatase, Interstitial collagenase
Cadral	CADRALAZINE		marketed	cadralazine	Myeloperoxidase, Voltage-dependent L-type calcium channel subunit alpha-1C
L-Tryptophan	TRYPTOPHAN		marketed	tryptophan	Myeloperoxidase, Extracellular calcium-sensing receptor, Probable G-protein coupled receptor 139

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
I.M. Sechenov First Moscow State Medical University · 1 drug in this class
Kenya Medical Research Institute · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
RWTH Aachen University · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZA capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/aza-capsules. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing